Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation

American Journal of Hematology

Volumn 83, Issue 6, 2008, Pages 472-476

  Asano Mori, Yuki ^a,b   Kanda, Yoshinobu ^a   Oshima, Kumi ^a   Kako, Shinichi ^a   Shinohara, Akihito ^a   Nakasone, Hideki ^a   Sato, Hiroyuki ^a   Watanabe, Takuro ^a   Hosoya, Noriko ^c   Izutsu, Koji ^a   Asai, Takashi ^a   Hangaishi, Akira ^a   Motokura, Tom ^a   Chiba, Shigeru ^c   Kurokawa, Mineo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; GANCICLOVIR; GEMCITABINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY; VALACICLOVIR;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHEMOPROPHYLAXIS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HERPES ZOSTER; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; INFECTION RISK; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION;

ACYCLOVIR; ADULT; ANTIVIRAL AGENTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; JAPAN; MALE; PREMEDICATION; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 44349179666     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21152     Document Type: Article

References (17)

1. Locksley RM, Flournoy N, Sullivan KM, et al. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985;152:1172-1181.
2. Arvin AM. Varicella-zoster virus: Pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2000;6:219-230.
3. Han CS, Miller W, Haake R, et al. Varicella zoster infection after bone marrow transplantation: Incidence, risk factors and complications. Bone Marrow Transplant 1994;13:277-283.
4. Ljungman P, Wilczek H, Gahrton G, et al. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplant 1986;1:185-192.
5. Koc Y, Miller KB, Schenkein DP, et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: Frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000;6:44-49.
6. Selby PJ, Powles RL, Easton D, et al. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br J Cancer 1989;59:434-438.
7. Steer CB, Szer J, Sasadeusz J, et al. Varicella-zoster infection after allogeneic bone marrow transplantation: Incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant 2000;25:657-664.
8. Boeckh M, Kim HW, Flowers ME, et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation - A randomized double-blind placebo-controlled study. Blood 2006;107:1800-1805.
9. Thomson KJ, Hart DP, Banerjee L, et al. The effect of low-dose acyclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005;35:1065-1069.
10. Kanda Y, Mineishi S, Saito T, et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;28:689-692.
11. Wilson A, Sharp M, Koropchak CM, et al. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 1992;165:119-126.
12. Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002;347:26-34.
13. Niiya H, Kanda Y, Saito T, et al. Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan. Hematologica 2001;86:1071-1074.
14. Kanda Y, Komatsu Y, Akahane M, et al. Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation. Transplantation 2005;79:821-827.
15. Kanda Y, Oshima K, Asano-Mori Y, et al. In vivo alemtuzumab enables haploidentical HLA-mismatched hematopoietic stem cell transplantation without ex vivo graft manipulation. Transplantation 2005;79:1351-1357.
16. Asano-Mori Y, Oshima K, Sakata-Yanagimoto M, et al. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation. Bone Marrow Transplant 2005;36:813-619.
17. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999;18:695-706.